295 related articles for article (PubMed ID: 23694857)
1. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity.
Strid H; Simrén M; Lasson A; Isaksson S; Stridsberg M; Öhman L
J Crohns Colitis; 2013 Dec; 7(12):e615-22. PubMed ID: 23694857
[TBL] [Abstract][Full Text] [Related]
2. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms?
Ohman L; Stridsberg M; Isaksson S; Jerlstad P; Simrén M
Am J Gastroenterol; 2012 Mar; 107(3):440-7. PubMed ID: 22233694
[TBL] [Abstract][Full Text] [Related]
3. Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis.
Wagner M; Stridsberg M; Peterson CG; Sangfelt P; Lampinen M; Carlson M
Inflammation; 2013 Aug; 36(4):855-61. PubMed ID: 23423580
[TBL] [Abstract][Full Text] [Related]
4. Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms.
Shulman RJ; Öhman L; Stridsberg M; Cain K; Simrén M; Heitkemper M
Neurogastroenterol Motil; 2019 Jan; 31(1):e13486. PubMed ID: 30298961
[TBL] [Abstract][Full Text] [Related]
5. Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II.
Portela-Gomes GM; Grimelius L; Stridsberg M
Regul Pept; 2010 Nov; 165(1):30-5. PubMed ID: 20550951
[TBL] [Abstract][Full Text] [Related]
6. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours.
Stridsberg M; Eriksson B; Janson ET
Regul Pept; 2008 Jun; 148(1-3):95-8. PubMed ID: 18448176
[TBL] [Abstract][Full Text] [Related]
7. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
[TBL] [Abstract][Full Text] [Related]
8. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
9. Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects.
Sundin J; Stridsberg M; Tap J; Derrien M; Le Nevé B; Doré J; Törnblom H; Simrén M; Öhman L
Sci Rep; 2018 Nov; 8(1):16821. PubMed ID: 30429499
[TBL] [Abstract][Full Text] [Related]
10. Rapid Fecal Calprotectin Testing Predicts Mucosal Healing Better than C-reactive Protein and Serum Tumor Necrosis Factor α in Patients with Ulcerative Colitis.
Voiosu T; Benguş A; Bălănescu P; Dinu R; Voiosu A; Băicuş C; Mateescu B
Rom J Intern Med; 2015; 53(3):253-60. PubMed ID: 26710501
[TBL] [Abstract][Full Text] [Related]
11. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
12. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis.
Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A
Digestion; 2016; 93(4):300-8. PubMed ID: 27220673
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
[TBL] [Abstract][Full Text] [Related]
14. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
Burri E; Beglinger C; von Felten S; Lehmann FS
Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining of human islet cells with region-specific antibodies against secretogranins II and III.
Stridsberg M; Grimelius L; Portela-Gomes GM
J Anat; 2008 Mar; 212(3):229-34. PubMed ID: 18221483
[TBL] [Abstract][Full Text] [Related]
17. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
18. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis.
De Vos M; Dewit O; D'Haens G; Baert F; Fontaine F; Vermeire S; Franchimont D; Moreels T; Staessen D; Terriere L; Vander Cruyssen B; Louis E;
J Crohns Colitis; 2012 Jun; 6(5):557-62. PubMed ID: 22398050
[TBL] [Abstract][Full Text] [Related]
19. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
Yamamoto T; Shiraki M; Bamba T; Umegae S; Matsumoto K
Int J Colorectal Dis; 2014 Apr; 29(4):485-91. PubMed ID: 24343276
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of chromogranins and secretogranins correlate with the progress and severity of Parkinson's disease.
Xu DJ; Wei LY; Li HF; Zhang WQ
Kaohsiung J Med Sci; 2019 Mar; 35(3):146-150. PubMed ID: 30887724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
